Nebentan potassium (Standard)
Nebentan potassium (Standard) (GT-2331 maleate (Standard)) is the analytical standard of Nebentan (potassium) (HY-106994A). This product is intended for research and analytical applications. Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo.
For research use only. We do not sell to patients.
- CAS No.: 342005-82-7
- Formula: C24H20KN5O5S
- Molecular Weight:529.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-15894A
BQ-788ETB Receptor Antagonist -
HY-A0013
BosentanET-1 Inhibtior -
HY-11103
Sitaxsentan sodiumEndothelin A Receptor Antagonist -
HY-106994A
Nebentan potassiumET(A) Receptor Antagonist -
HY-A0013A
Bosentan hydrateET1 Receptor Antagonist -
HY-15403A
Atrasentan hydrochlorideETA Receptor Antagonist -
HY-15895
AprocitentanEndothelin Receptor Antagonist -
HY-15403
AtrasentanEndothelin Receptor Antagonist -
HY-17352
ClazosentanETA Receptor Antagonist -
HY-P0202
Endothelin 1 (swine, human)Vasoconstrictor -
HY-17351
TezosentanET Receptor Antagonist -
HY-16465
IRL-1620ETB Agonist
Biological Activity
Description
Chemical Information
-
CAS No. 342005-82-7
-
Molecular Weight 529.61
-
Formula C24H20KN5O5S
-
SMILES
O=S(/C=C/C1=CC=CC=C1)([N-]C2=NC(C3=NC=CC=N3)=NC(OC)=C2OC4=CC=CC=C4OC)=O.[K+]
-
Synonyms
YM598 (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
[1]. Hironori Yuyama, et al. Pharmacological Characterization of YM598, an Orally Active and Highly Potent Selective Endothelin ET(A) Receptor Antagonist. Eur J Pharmacol. 2003 Sep 30;478(1):61-71. [Content Brief]
[2]. Akira Fujimori, et al. YM598, an Orally Active ET(A) Receptor Antagonist, Ameliorates the Progression of Cardiopulmonary Changes and Both-Side Heart Failure in Rats With Cor Pulmonale and Myocardial Infarction. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S354-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nebentan potassium (Standard) Related Classifications
HY-106994AR Related Classifications
Powered by Bioz